[go: up one dir, main page]

WO2002080974A1 - Novel medicinal use of cytokine production inhibitor - Google Patents

Novel medicinal use of cytokine production inhibitor Download PDF

Info

Publication number
WO2002080974A1
WO2002080974A1 PCT/JP2002/003354 JP0203354W WO02080974A1 WO 2002080974 A1 WO2002080974 A1 WO 2002080974A1 JP 0203354 W JP0203354 W JP 0203354W WO 02080974 A1 WO02080974 A1 WO 02080974A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine production
production inhibitor
medicinal use
novel medicinal
antiinflammatory agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/003354
Other languages
French (fr)
Japanese (ja)
Inventor
Shigeru Ushiyama
Tomio Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of WO2002080974A1 publication Critical patent/WO2002080974A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A drug having relieved side effects of a nonsteroidal antiinflammatory agent which is to be used for simultaneously, separately or intermittently administering the nonsteroidal antiinflammatory agent with an inflammatory cytokine production inhibitor.
PCT/JP2002/003354 2001-04-04 2002-04-03 Novel medicinal use of cytokine production inhibitor Ceased WO2002080974A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-105615 2001-04-04
JP2001105615 2001-04-04

Publications (1)

Publication Number Publication Date
WO2002080974A1 true WO2002080974A1 (en) 2002-10-17

Family

ID=18958272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003354 Ceased WO2002080974A1 (en) 2001-04-04 2002-04-03 Novel medicinal use of cytokine production inhibitor

Country Status (1)

Country Link
WO (1) WO2002080974A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (en) * 2002-07-19 2004-01-29 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595546A1 (en) * 1992-10-28 1994-05-04 Shionogi & Co., Ltd. Benzylidene derivatives
EP0799823A1 (en) * 1996-04-05 1997-10-08 Sankyo Company Limited 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses
EP0865788A1 (en) * 1995-09-13 1998-09-23 Kabushiki Kaisha Yakult Honsha Specific cyclooxygenase 2 inhibitor and anti-inflammatory agent
WO1999006404A1 (en) * 1997-07-29 1999-02-11 Almirall Prodesfarma S.A. 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
JPH11180871A (en) * 1997-09-26 1999-07-06 Sankyo Co Ltd Medicine containing 1,2-diphenylpyrrole derivative
EP1070711A2 (en) * 1999-07-21 2001-01-24 Sankyo Company Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595546A1 (en) * 1992-10-28 1994-05-04 Shionogi & Co., Ltd. Benzylidene derivatives
EP0865788A1 (en) * 1995-09-13 1998-09-23 Kabushiki Kaisha Yakult Honsha Specific cyclooxygenase 2 inhibitor and anti-inflammatory agent
EP0799823A1 (en) * 1996-04-05 1997-10-08 Sankyo Company Limited 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses
WO1999006404A1 (en) * 1997-07-29 1999-02-11 Almirall Prodesfarma S.A. 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
JPH11180871A (en) * 1997-09-26 1999-07-06 Sankyo Co Ltd Medicine containing 1,2-diphenylpyrrole derivative
EP1070711A2 (en) * 1999-07-21 2001-01-24 Sankyo Company Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (en) * 2002-07-19 2004-01-29 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compound

Similar Documents

Publication Publication Date Title
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002328092A1 (en) Bicyclic compound, production and use as hiv inhibitors
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
DK1296670T3 (en) Therapeutic fatty acid combinations
ZA200305173B (en) Omega-Aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells.
MXPA03008045A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors.
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
AU2002360375A1 (en) Synthesis strategies based on the appropriate use of inductance effects
NO20024528L (en) Protease inhibitor, pharmaceutical composition and use of the compound
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2001270778A1 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2003051398A8 (en) Parenteral composition of paracetamol
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003235798A1 (en) Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
AU2002332488A1 (en) R-bambuterol, its preparation and therapeutic uses
PT1638943E (en) Novel imidazole derivatives, the production thereof, and the use of the same as a medicament
MXPA03008186A (en) Anti-thrombotic carboxylic acid amides, the production thereof and use of the same as medicaments.
WO2002080974A1 (en) Novel medicinal use of cytokine production inhibitor
WO2001049651A3 (en) Aminomethyl-phenyl-cyclohexanone derivatives
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
NO20032006L (en) Use of melagatran for the manufacture of a medicament for the treatment of ischemic disorders
IT1317073B1 (en) Production of phenylbutyric acid esters for therapeutic use
EP1157705A3 (en) Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP